This video may appear OT, but view/listen carefully. Dr. Missling is describing the advantages AVXL is finding in targeting an upstream target in epilepsy & Alzheimers with its main pipeline biologic: http://www.epilepsy.com/accelerating-new-therapies/2016-epilepsy-pipeline-conference/session-ix-clinical-drugs#14 Rett's syndrome emphasis.